Sai Life Sciences Limited has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company’s Board of Directors reviewed and approved these results on August 6, 2026. The filing includes the company’s financial performance for the period, along with the limited review report from its statutory auditors, Deloitte Haskins & Sells LLP. Key figures indicate the company’s revenue and profitability for the quarter.
Sai Life Sciences Announces Q1 FY27 Financial Results
Sai Life Sciences Limited has officially released its unaudited financial results for the first quarter of the financial year 2027, which concluded on June 30, 2026. The Board of Directors of the company convened on August 6, 2026, to consider and approve these financial statements.
Standalone Financial Highlights
For the quarter ended June 30, 2026, the unaudited standalone financial results show a total income of ₹5,502.72 million. The profit before tax (PBT) stood at ₹953.34 million, while the profit after tax (PAT) was reported at ₹713.39 million. These figures reflect the company’s operational and financial performance during the period.
The company also noted the limited review report provided by its statutory auditors, M/s. Deloitte Haskins & Sells LLP, for the quarter.
Consolidated Financial Performance
On a consolidated basis, Sai Life Sciences Limited reported a total income of ₹5,578.28 million for the quarter ending June 30, 2026. The profit before tax for the consolidated entity was ₹979.74 million, with the profit after tax reported at ₹732.85 million.
The financial statements also encompass the results of the company’s subsidiaries, including Sai Life Sciences Inc, USA; Sai Life GmBH, Germany; and Sai Life Pharma Private Limited, India, collectively referred to as “the Group”.
Other Comprehensive Income and Equity
The reports also detail other comprehensive income/(loss) and movements in equity. For the standalone entity, total comprehensive income for the period was ₹910.01 million. The consolidated total comprehensive income amounted to ₹930.23 million.
Earnings per equity share (EPS) for the standalone results were ₹3.36 (Basic) and ₹3.33 (Diluted). For the consolidated results, the EPS was ₹3.46 (Basic) and ₹3.42 (Diluted).
Operational Notes
During the quarter ended June 30, 2026, the Company allotted 506,782 equity shares of ₹1 each, resulting from the exercise of employee stock options.
Source: BSE
